Inflammatory myositis associated with anti‐U1‐small nuclear ribonucleoprotein antibodies: a subset of myositis associated with a favourable outcome

Objectives. Inflammatory myositides are rare chronic disorders which may be either isolated or associated with other conditions such as connective tissue diseases or neoplasia. A large variety of autoantibodies can be detected in patients with myositis, some of which have a diagnostic and/or a progn...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:British journal of rheumatology 2002-09, Vol.41 (9), p.1040-1046
Hauptverfasser: Coppo, P., Clauvel, J. P., Bengoufa, D., Oksenhendler, E., Lacroix, C., Lassoued, K.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 1046
container_issue 9
container_start_page 1040
container_title British journal of rheumatology
container_volume 41
creator Coppo, P.
Clauvel, J. P.
Bengoufa, D.
Oksenhendler, E.
Lacroix, C.
Lassoued, K.
description Objectives. Inflammatory myositides are rare chronic disorders which may be either isolated or associated with other conditions such as connective tissue diseases or neoplasia. A large variety of autoantibodies can be detected in patients with myositis, some of which have a diagnostic and/or a prognostic value. Myositis associated with anti‐U1‐small nuclear ribonucleoprotein antibodies (anti‐U1‐snRNP Abs) are usually considered as overlapping syndromes, mainly mixed connective tissue diseases (MCTD) in which muscle symptoms occur insidiously during the disease course and are characterized by a favourable outcome. Methods. The clinical, biological, immunological and pathological findings as well as the outcome of five patients with anti‐U1‐snRNP‐associated myositis were retrospectively analysed. Results. Patients were mainly black females. In all five patients, myositis was the predominant manifestation at presentation. Associated conditions consisted of interstitial lung disease (ILD) (three), arthritis (three) and neurological symptoms (two). No patient presented Raynaud's phenomenon nor met criteria for MCTD. Biological inflammatory features, rheumatoid factor and polyclonal hypergammaglobulinaemia were present in all cases. Besides anti‐U1‐snRNP Abs, one patient had anti‐Ro/SSA and anti‐La/SSB Abs at presentation and one additional patient developed anti‐double‐stranded‐DNA and anti‐Sm Abs after a follow‐up of more than 4 yr. No patient had anti‐PM/sclerosis (Scl) nor anti‐aminoacyl‐tRNA synthetase Abs. All patients dramatically improved with steroids, and reached complete remission (CR) within 3 weeks. Two patients relapsed 18 months after CR. They both reached rapidly second CR using steroids associated or not with oral methotrexate. Conclusion. Our data suggest that anti‐U1‐snRNP Abs may define a subset of myositis characterized by a favourable outcome, though often associated with ILD and/or neurological manifestations.
doi_str_mv 10.1093/rheumatology/41.9.1040
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_72057559</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>72057559</sourcerecordid><originalsourceid>FETCH-LOGICAL-c481t-5c42c2ae450e73f8d22fd91128de58d4bf0ac6a78b0f43246ddc6e66ff74ddd23</originalsourceid><addsrcrecordid>eNqFkctuFDEQRVsIRB7wC5GFBLtJ_O5udigiDzESGyIQG6vaD-LgbgfbDZkdn8CO_-NL8GRGCWIBG7tUPnVV17dpDgg-JLhnR-nSziOUGOKn1REnh31tc_yg2SVc0gVmjD68qynfafZyvsIYC8K6x80OoRT3mPW7zc_zyQUY11JphcZVzL74jCDnqD0Ua9A3Xy4RTMX_-v7jgtQjjxACmmYdLCSU_BBv63idYrF-umWHaLzNLxGgPA_ZFhTdP8SRg69xTjAEi-JcdBztk-aRg5Dt0-2931ycvH53fLZYvj09P361XGjekbIQmlNNwXKBbctcZyh1pieEdsaKzvDBYdAS2m7AjtePkMZoaaV0ruXGGMr2mxcb3br9l9nmokaftQ0BJhvnrFqKRStE_1-QEsJpS9bgs7_Aq-ptqiYU6YWUVFJcIbmBdIo5J-vUdfIjpJUiWK0DVn8GrDhRvVoHXAcPturzMFpzP7ZNtALPtwBkDcElmLTP9xzrCRWcVG6x4Xwu9ubuHdJnJVvWCnX24aOS_PTN--5kqZbsNwazx-4</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>195662620</pqid></control><display><type>article</type><title>Inflammatory myositis associated with anti‐U1‐small nuclear ribonucleoprotein antibodies: a subset of myositis associated with a favourable outcome</title><source>MEDLINE</source><source>Oxford University Press Journals All Titles (1996-Current)</source><source>Alma/SFX Local Collection</source><creator>Coppo, P. ; Clauvel, J. P. ; Bengoufa, D. ; Oksenhendler, E. ; Lacroix, C. ; Lassoued, K.</creator><creatorcontrib>Coppo, P. ; Clauvel, J. P. ; Bengoufa, D. ; Oksenhendler, E. ; Lacroix, C. ; Lassoued, K.</creatorcontrib><description>Objectives. Inflammatory myositides are rare chronic disorders which may be either isolated or associated with other conditions such as connective tissue diseases or neoplasia. A large variety of autoantibodies can be detected in patients with myositis, some of which have a diagnostic and/or a prognostic value. Myositis associated with anti‐U1‐small nuclear ribonucleoprotein antibodies (anti‐U1‐snRNP Abs) are usually considered as overlapping syndromes, mainly mixed connective tissue diseases (MCTD) in which muscle symptoms occur insidiously during the disease course and are characterized by a favourable outcome. Methods. The clinical, biological, immunological and pathological findings as well as the outcome of five patients with anti‐U1‐snRNP‐associated myositis were retrospectively analysed. Results. Patients were mainly black females. In all five patients, myositis was the predominant manifestation at presentation. Associated conditions consisted of interstitial lung disease (ILD) (three), arthritis (three) and neurological symptoms (two). No patient presented Raynaud's phenomenon nor met criteria for MCTD. Biological inflammatory features, rheumatoid factor and polyclonal hypergammaglobulinaemia were present in all cases. Besides anti‐U1‐snRNP Abs, one patient had anti‐Ro/SSA and anti‐La/SSB Abs at presentation and one additional patient developed anti‐double‐stranded‐DNA and anti‐Sm Abs after a follow‐up of more than 4 yr. No patient had anti‐PM/sclerosis (Scl) nor anti‐aminoacyl‐tRNA synthetase Abs. All patients dramatically improved with steroids, and reached complete remission (CR) within 3 weeks. Two patients relapsed 18 months after CR. They both reached rapidly second CR using steroids associated or not with oral methotrexate. Conclusion. Our data suggest that anti‐U1‐snRNP Abs may define a subset of myositis characterized by a favourable outcome, though often associated with ILD and/or neurological manifestations.</description><identifier>ISSN: 1462-0324</identifier><identifier>ISSN: 1460-2172</identifier><identifier>EISSN: 1462-0332</identifier><identifier>EISSN: 1460-2172</identifier><identifier>DOI: 10.1093/rheumatology/41.9.1040</identifier><identifier>PMID: 12209039</identifier><language>eng</language><publisher>Oxford: Oxford University Press</publisher><subject>Adult ; Anti‐ribonucleoprotein antibodies ; Autoantibodies ; Autoantibodies - immunology ; Biological and medical sciences ; Connective Tissue Diseases - complications ; Connective Tissue Diseases - immunology ; Connective Tissue Diseases - pathology ; Dermatomyositis - complications ; Dermatomyositis - immunology ; Dermatomyositis - therapy ; Diseases of striated muscles. Neuromuscular diseases ; Electromyography ; Female ; Glucocorticoids - therapeutic use ; Humans ; Immunoglobulins, Intravenous - therapeutic use ; Inflammatory myositis ; Male ; Medical sciences ; Middle Aged ; Muscle Weakness - etiology ; Muscle Weakness - immunology ; Muscle Weakness - therapy ; Muscle, Skeletal - enzymology ; Muscle, Skeletal - pathology ; Muscle, Skeletal - physiopathology ; Neurology ; Retrospective Studies ; Ribonucleoprotein, U1 Small Nuclear - immunology ; RNA, Small Nuclear - immunology ; Treatment Outcome</subject><ispartof>British journal of rheumatology, 2002-09, Vol.41 (9), p.1040-1046</ispartof><rights>2002 INIST-CNRS</rights><rights>Copyright Oxford University Press(England) Sep 2002</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c481t-5c42c2ae450e73f8d22fd91128de58d4bf0ac6a78b0f43246ddc6e66ff74ddd23</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27915,27916</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=13912541$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/12209039$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Coppo, P.</creatorcontrib><creatorcontrib>Clauvel, J. P.</creatorcontrib><creatorcontrib>Bengoufa, D.</creatorcontrib><creatorcontrib>Oksenhendler, E.</creatorcontrib><creatorcontrib>Lacroix, C.</creatorcontrib><creatorcontrib>Lassoued, K.</creatorcontrib><title>Inflammatory myositis associated with anti‐U1‐small nuclear ribonucleoprotein antibodies: a subset of myositis associated with a favourable outcome</title><title>British journal of rheumatology</title><addtitle>Rheumatology</addtitle><description>Objectives. Inflammatory myositides are rare chronic disorders which may be either isolated or associated with other conditions such as connective tissue diseases or neoplasia. A large variety of autoantibodies can be detected in patients with myositis, some of which have a diagnostic and/or a prognostic value. Myositis associated with anti‐U1‐small nuclear ribonucleoprotein antibodies (anti‐U1‐snRNP Abs) are usually considered as overlapping syndromes, mainly mixed connective tissue diseases (MCTD) in which muscle symptoms occur insidiously during the disease course and are characterized by a favourable outcome. Methods. The clinical, biological, immunological and pathological findings as well as the outcome of five patients with anti‐U1‐snRNP‐associated myositis were retrospectively analysed. Results. Patients were mainly black females. In all five patients, myositis was the predominant manifestation at presentation. Associated conditions consisted of interstitial lung disease (ILD) (three), arthritis (three) and neurological symptoms (two). No patient presented Raynaud's phenomenon nor met criteria for MCTD. Biological inflammatory features, rheumatoid factor and polyclonal hypergammaglobulinaemia were present in all cases. Besides anti‐U1‐snRNP Abs, one patient had anti‐Ro/SSA and anti‐La/SSB Abs at presentation and one additional patient developed anti‐double‐stranded‐DNA and anti‐Sm Abs after a follow‐up of more than 4 yr. No patient had anti‐PM/sclerosis (Scl) nor anti‐aminoacyl‐tRNA synthetase Abs. All patients dramatically improved with steroids, and reached complete remission (CR) within 3 weeks. Two patients relapsed 18 months after CR. They both reached rapidly second CR using steroids associated or not with oral methotrexate. Conclusion. Our data suggest that anti‐U1‐snRNP Abs may define a subset of myositis characterized by a favourable outcome, though often associated with ILD and/or neurological manifestations.</description><subject>Adult</subject><subject>Anti‐ribonucleoprotein antibodies</subject><subject>Autoantibodies</subject><subject>Autoantibodies - immunology</subject><subject>Biological and medical sciences</subject><subject>Connective Tissue Diseases - complications</subject><subject>Connective Tissue Diseases - immunology</subject><subject>Connective Tissue Diseases - pathology</subject><subject>Dermatomyositis - complications</subject><subject>Dermatomyositis - immunology</subject><subject>Dermatomyositis - therapy</subject><subject>Diseases of striated muscles. Neuromuscular diseases</subject><subject>Electromyography</subject><subject>Female</subject><subject>Glucocorticoids - therapeutic use</subject><subject>Humans</subject><subject>Immunoglobulins, Intravenous - therapeutic use</subject><subject>Inflammatory myositis</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Muscle Weakness - etiology</subject><subject>Muscle Weakness - immunology</subject><subject>Muscle Weakness - therapy</subject><subject>Muscle, Skeletal - enzymology</subject><subject>Muscle, Skeletal - pathology</subject><subject>Muscle, Skeletal - physiopathology</subject><subject>Neurology</subject><subject>Retrospective Studies</subject><subject>Ribonucleoprotein, U1 Small Nuclear - immunology</subject><subject>RNA, Small Nuclear - immunology</subject><subject>Treatment Outcome</subject><issn>1462-0324</issn><issn>1460-2172</issn><issn>1462-0332</issn><issn>1460-2172</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2002</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkctuFDEQRVsIRB7wC5GFBLtJ_O5udigiDzESGyIQG6vaD-LgbgfbDZkdn8CO_-NL8GRGCWIBG7tUPnVV17dpDgg-JLhnR-nSziOUGOKn1REnh31tc_yg2SVc0gVmjD68qynfafZyvsIYC8K6x80OoRT3mPW7zc_zyQUY11JphcZVzL74jCDnqD0Ua9A3Xy4RTMX_-v7jgtQjjxACmmYdLCSU_BBv63idYrF-umWHaLzNLxGgPA_ZFhTdP8SRg69xTjAEi-JcdBztk-aRg5Dt0-2931ycvH53fLZYvj09P361XGjekbIQmlNNwXKBbctcZyh1pieEdsaKzvDBYdAS2m7AjtePkMZoaaV0ruXGGMr2mxcb3br9l9nmokaftQ0BJhvnrFqKRStE_1-QEsJpS9bgs7_Aq-ptqiYU6YWUVFJcIbmBdIo5J-vUdfIjpJUiWK0DVn8GrDhRvVoHXAcPturzMFpzP7ZNtALPtwBkDcElmLTP9xzrCRWcVG6x4Xwu9ubuHdJnJVvWCnX24aOS_PTN--5kqZbsNwazx-4</recordid><startdate>20020901</startdate><enddate>20020901</enddate><creator>Coppo, P.</creator><creator>Clauvel, J. P.</creator><creator>Bengoufa, D.</creator><creator>Oksenhendler, E.</creator><creator>Lacroix, C.</creator><creator>Lassoued, K.</creator><general>Oxford University Press</general><general>Oxford Publishing Limited (England)</general><scope>BSCLL</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QP</scope><scope>K9.</scope><scope>NAPCQ</scope><scope>7TM</scope><scope>7X8</scope></search><sort><creationdate>20020901</creationdate><title>Inflammatory myositis associated with anti‐U1‐small nuclear ribonucleoprotein antibodies: a subset of myositis associated with a favourable outcome</title><author>Coppo, P. ; Clauvel, J. P. ; Bengoufa, D. ; Oksenhendler, E. ; Lacroix, C. ; Lassoued, K.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c481t-5c42c2ae450e73f8d22fd91128de58d4bf0ac6a78b0f43246ddc6e66ff74ddd23</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2002</creationdate><topic>Adult</topic><topic>Anti‐ribonucleoprotein antibodies</topic><topic>Autoantibodies</topic><topic>Autoantibodies - immunology</topic><topic>Biological and medical sciences</topic><topic>Connective Tissue Diseases - complications</topic><topic>Connective Tissue Diseases - immunology</topic><topic>Connective Tissue Diseases - pathology</topic><topic>Dermatomyositis - complications</topic><topic>Dermatomyositis - immunology</topic><topic>Dermatomyositis - therapy</topic><topic>Diseases of striated muscles. Neuromuscular diseases</topic><topic>Electromyography</topic><topic>Female</topic><topic>Glucocorticoids - therapeutic use</topic><topic>Humans</topic><topic>Immunoglobulins, Intravenous - therapeutic use</topic><topic>Inflammatory myositis</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Muscle Weakness - etiology</topic><topic>Muscle Weakness - immunology</topic><topic>Muscle Weakness - therapy</topic><topic>Muscle, Skeletal - enzymology</topic><topic>Muscle, Skeletal - pathology</topic><topic>Muscle, Skeletal - physiopathology</topic><topic>Neurology</topic><topic>Retrospective Studies</topic><topic>Ribonucleoprotein, U1 Small Nuclear - immunology</topic><topic>RNA, Small Nuclear - immunology</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Coppo, P.</creatorcontrib><creatorcontrib>Clauvel, J. P.</creatorcontrib><creatorcontrib>Bengoufa, D.</creatorcontrib><creatorcontrib>Oksenhendler, E.</creatorcontrib><creatorcontrib>Lacroix, C.</creatorcontrib><creatorcontrib>Lassoued, K.</creatorcontrib><collection>Istex</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Calcium &amp; Calcified Tissue Abstracts</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Nursing &amp; Allied Health Premium</collection><collection>Nucleic Acids Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>British journal of rheumatology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Coppo, P.</au><au>Clauvel, J. P.</au><au>Bengoufa, D.</au><au>Oksenhendler, E.</au><au>Lacroix, C.</au><au>Lassoued, K.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Inflammatory myositis associated with anti‐U1‐small nuclear ribonucleoprotein antibodies: a subset of myositis associated with a favourable outcome</atitle><jtitle>British journal of rheumatology</jtitle><addtitle>Rheumatology</addtitle><date>2002-09-01</date><risdate>2002</risdate><volume>41</volume><issue>9</issue><spage>1040</spage><epage>1046</epage><pages>1040-1046</pages><issn>1462-0324</issn><issn>1460-2172</issn><eissn>1462-0332</eissn><eissn>1460-2172</eissn><abstract>Objectives. Inflammatory myositides are rare chronic disorders which may be either isolated or associated with other conditions such as connective tissue diseases or neoplasia. A large variety of autoantibodies can be detected in patients with myositis, some of which have a diagnostic and/or a prognostic value. Myositis associated with anti‐U1‐small nuclear ribonucleoprotein antibodies (anti‐U1‐snRNP Abs) are usually considered as overlapping syndromes, mainly mixed connective tissue diseases (MCTD) in which muscle symptoms occur insidiously during the disease course and are characterized by a favourable outcome. Methods. The clinical, biological, immunological and pathological findings as well as the outcome of five patients with anti‐U1‐snRNP‐associated myositis were retrospectively analysed. Results. Patients were mainly black females. In all five patients, myositis was the predominant manifestation at presentation. Associated conditions consisted of interstitial lung disease (ILD) (three), arthritis (three) and neurological symptoms (two). No patient presented Raynaud's phenomenon nor met criteria for MCTD. Biological inflammatory features, rheumatoid factor and polyclonal hypergammaglobulinaemia were present in all cases. Besides anti‐U1‐snRNP Abs, one patient had anti‐Ro/SSA and anti‐La/SSB Abs at presentation and one additional patient developed anti‐double‐stranded‐DNA and anti‐Sm Abs after a follow‐up of more than 4 yr. No patient had anti‐PM/sclerosis (Scl) nor anti‐aminoacyl‐tRNA synthetase Abs. All patients dramatically improved with steroids, and reached complete remission (CR) within 3 weeks. Two patients relapsed 18 months after CR. They both reached rapidly second CR using steroids associated or not with oral methotrexate. Conclusion. Our data suggest that anti‐U1‐snRNP Abs may define a subset of myositis characterized by a favourable outcome, though often associated with ILD and/or neurological manifestations.</abstract><cop>Oxford</cop><pub>Oxford University Press</pub><pmid>12209039</pmid><doi>10.1093/rheumatology/41.9.1040</doi><tpages>7</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1462-0324
ispartof British journal of rheumatology, 2002-09, Vol.41 (9), p.1040-1046
issn 1462-0324
1460-2172
1462-0332
1460-2172
language eng
recordid cdi_proquest_miscellaneous_72057559
source MEDLINE; Oxford University Press Journals All Titles (1996-Current); Alma/SFX Local Collection
subjects Adult
Anti‐ribonucleoprotein antibodies
Autoantibodies
Autoantibodies - immunology
Biological and medical sciences
Connective Tissue Diseases - complications
Connective Tissue Diseases - immunology
Connective Tissue Diseases - pathology
Dermatomyositis - complications
Dermatomyositis - immunology
Dermatomyositis - therapy
Diseases of striated muscles. Neuromuscular diseases
Electromyography
Female
Glucocorticoids - therapeutic use
Humans
Immunoglobulins, Intravenous - therapeutic use
Inflammatory myositis
Male
Medical sciences
Middle Aged
Muscle Weakness - etiology
Muscle Weakness - immunology
Muscle Weakness - therapy
Muscle, Skeletal - enzymology
Muscle, Skeletal - pathology
Muscle, Skeletal - physiopathology
Neurology
Retrospective Studies
Ribonucleoprotein, U1 Small Nuclear - immunology
RNA, Small Nuclear - immunology
Treatment Outcome
title Inflammatory myositis associated with anti‐U1‐small nuclear ribonucleoprotein antibodies: a subset of myositis associated with a favourable outcome
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-15T02%3A07%3A19IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Inflammatory%20myositis%20associated%20with%20anti%E2%80%90U1%E2%80%90small%20nuclear%20ribonucleoprotein%20antibodies:%20a%20subset%20of%20myositis%20associated%20with%20a%20favourable%20outcome&rft.jtitle=British%20journal%20of%20rheumatology&rft.au=Coppo,%20P.&rft.date=2002-09-01&rft.volume=41&rft.issue=9&rft.spage=1040&rft.epage=1046&rft.pages=1040-1046&rft.issn=1462-0324&rft.eissn=1462-0332&rft_id=info:doi/10.1093/rheumatology/41.9.1040&rft_dat=%3Cproquest_cross%3E72057559%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=195662620&rft_id=info:pmid/12209039&rfr_iscdi=true